Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Zelicapavir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enanta Pharma Unveils Zelicapavir And EDP-323, Data For RSV
    Enanta Pharma Unveils Zelicapavir And EDP-323, Data For RSV

    20 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251020795690/en/Enanta-Pharmaceuticals-Presents-New-Data-for-Zelicapavir-its-N-Protein-Inhibitor-and-EDP-323-its-L-Protein-Inhibitor-Both-in-Development-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-at-IDWeek-2025

    BUSINESSWIRE
    20 Oct 2025
    Share Share
    Enanta To Present Zelicapavir, EDP-323 RSV Data At IDWeek 2025
    Enanta To Present Zelicapavir, EDP-323 RSV Data At IDWeek 2025

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-fo

    PHARMIWEB
    07 Oct 2025
    Share Share
    Enanta To Share Ph 2b Zelicapavir Results In RSV High-Risk Adults
    Enanta To Share Ph 2b Zelicapavir Results In RSV High-Risk Adults

    26 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250926821731/en/Enanta-Pharmaceuticals-to-Present-Topline-Results-from-its-Phase-2b-Study-Evaluating-Zelicapavir-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-in-High-Risk-Adults

    BUSINESSWIRE
    26 Sep 2025
    Share Share
    Enanta Pharmaceuticals to Present Zelicapavir Data at ESPID
    Enanta Pharmaceuticals to Present Zelicapavir Data at ESPID

    22 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250522937132/en/Enanta-Pharmaceuticals-Announces-Data-from-its-Phase-2-Study-of-Zelicapavir-in-Children-with-Respiratory-Syncytial-Virus-to-be-Presented-at-the-43rd-Annual-ESPID-Meeting

    BUSINESSWIRE
    22 May 2025
    Share Share